ABO Blood Group Alleles and Prostate Cancer Risk: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3)
View/ Open
Author
Markt, Sarah
Shui, Irene
Unger, Robert
Urun, Yuksel
Berg, Christine
Black, Amanda
Brennan, Paul
Bueno-de-Mesquita, H. Bas
Gapstur, Susan
Giovannucci, Edward
Haiman, Christopher
Henderson, Brian
Hoover, Robert
Hunter, David
Key, Timothy
Khaw, Kay-Tee
Canzian, Federico
Larranga, Nerea
Le Marchand, Loic
Ma, Jing
Naccarati, Alessio
Siddiq, Afshan
Stattin, Par
Stevens, Victoria
Stram, Daniel
Tjønneland, Anne
Travis, Ruth
Trichopoulos, Dimitrios
Ziegler, Regina
Lindstrom, Sara
Kraft, Peter
Mucci, Lorelei
Choueiri, Toni
Wilson, Kathryn
Published Version
https://doi.org/10.1002/pros.23035Metadata
Show full item recordCitation
Markt, Sarah C., Irene M. Shui, Robert H. Unger, Yuksel Urun, Christine D. Berg, Amanda Black, Paul Brennan, et al. 2015. “ABO Blood Group Alleles and Prostate Cancer Risk: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3).” The Prostate 75 (15): 1677–81. https://doi.org/10.1002/pros.23035.Abstract
BACKGROUND. ABO blood group has been associated with risk of cancers of the pancreas, stomach, ovary, kidney, and skin, but has not been evaluated in relation to risk of aggressive prostate cancer.METHODS. We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). Unconditional logistic regression was used to calculate age and study-adjusted odds ratios and 95% confidence intervals for the association between blood type, genotype, and risk of aggressive prostate cancer (Gleason score >= 8 or locally advanced/metastatic disease (stage T3/T4/N1/M1). RESULTS . We found no association between ABO blood type and risk of aggressive prostate cancer (Type A: OR = 0.97, 95% CI = 0.87-1.08; Type B: OR = 0.92, 95% CI = n0.77-1.09; Type AB: OR = 1.25, 95% CI = 0.98-1.59, compared to Type O, respectively). Similarly, there was no association between "dose" of A or B alleles and aggressive prostate cancer risk. CONCLUSION S. ABO blood type was not associated with risk of aggressive prostate cancer. Prostate 75: 1677-1681, 2015.Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292506
Collections
- SPH Scholarly Articles [6392]
Contact administrator regarding this item (to report mistakes or request changes)